Suppr超能文献

β受体阻滞剂可引起肝硬化伴难治性腹水患者经皮穿刺放液后循环功能障碍:一项交叉研究。

Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.

机构信息

INSERM, U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3 Clichy, Paris, France.

出版信息

J Hepatol. 2011 Oct;55(4):794-9. doi: 10.1016/j.jhep.2011.01.034. Epub 2011 Feb 24.

Abstract

BACKGROUND & AIMS: In patients with cirrhosis and refractory ascites the role of beta-blockers in the development of paracentesis-induced circulatory dysfunction (PICD) is unknown. The aim of this study was to investigate the incidence of PICD before and after discontinuation of beta-blockers in patients with cirrhosis and refractory ascites. A self control cross-over study was performed.

METHODS

Patients with cirrhosis and refractory ascites treated with beta-blockers were selected. Heart rate, arterial pressure, and plasma renin concentrations (PRC) were collected before, immediately after and 1 week after large-volume paracentesis associated with intravenous albumin administration. Beta-blocker therapy was progressively discontinued after complete endoscopic eradication of varices. The clinical and biological evaluation was then repeated. The presence of PICD was defined as an increase in PRC of at least 50% above baseline 1 week after paracentesis.

RESULTS

Ten patients were included (nine men, mean age 59.1 ± 10.7 years old). The MELD score was 17.7 ± 4.4 and eight patients were Child-Pugh C. When patients were given beta-blockers, the heart rate did not change immediately after paracentesis while mean arterial pressure significantly decreased; PICD developed in eight patients. After beta-blockers were discontinued, the heart rate significantly increased immediately after paracentesis and mean arterial pressure significantly decreased; PICD only developed in one patient; the difference in the incidence of PICD was significant when these same patients were treated with beta-blockers.

CONCLUSIONS

The use of beta-blockers may be associated with a high risk of PICD in patients with cirrhosis and refractory ascites.

摘要

背景与目的

在肝硬化伴难治性腹水患者中,β受体阻滞剂在发生穿刺引流相关循环功能障碍(PICD)中的作用尚不清楚。本研究旨在探讨肝硬化伴难治性腹水患者停用β受体阻滞剂前后发生 PICD 的情况。采用自身对照交叉研究。

方法

选择接受β受体阻滞剂治疗的肝硬化伴难治性腹水患者。在大容量穿刺引流联合静脉白蛋白输注前后即刻、1 周时采集心率、动脉压和血浆肾素浓度(PRC)。完全内镜下消除静脉曲张后,逐步停用β受体阻滞剂。然后重复临床和生物学评估。定义 PICD 的存在为穿刺后 1 周时 PRC 比基线至少增加 50%。

结果

共纳入 10 例患者(9 例男性,平均年龄 59.1 ± 10.7 岁)。MELD 评分为 17.7 ± 4.4,8 例患者为 Child-Pugh C 级。给予β受体阻滞剂时,穿刺后即刻心率无变化,而平均动脉压显著降低;8 例患者发生 PICD。停用β受体阻滞剂后,穿刺后即刻心率显著增加,平均动脉压显著降低;仅 1 例患者发生 PICD;与这些患者使用β受体阻滞剂时相比,PICD 的发生率差异有统计学意义。

结论

β受体阻滞剂的使用可能与肝硬化伴难治性腹水患者发生 PICD 的风险增加有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验